{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T16:50:38Z","timestamp":1787590238196,"version":"build-2736575974"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"the Guangxi Natural Science Foundation","award":["No. 2025GXNSFHA069094"],"award-info":[{"award-number":["No. 2025GXNSFHA069094"]}]},{"name":"the Open Project Program of Key Laboratory of Early Prevention and Treatment for Regional High Frequency Tumor, Ministry of Education, Guangxi Medical University","award":["No. GKE-KF202006"],"award-info":[{"award-number":["No. GKE-KF202006"]}]},{"name":"the Key Laboratory of Pollution Exposure and Health Intervention of Zhejiang Province","award":["No. 202300011"],"award-info":[{"award-number":["No. 202300011"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"DOI":"10.1007\/s11096-025-02055-2","type":"journal-article","created":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T11:48:54Z","timestamp":1763984934000},"page":"274-283","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Bibliometric analysis of anti-angiogenic therapy in gastric cancer: research hotspots, trends, and emerging frontiers"],"prefix":"10.1007","volume":"48","author":[{"given":"Gaofeng","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaojuan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zujin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meijun","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihe","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenwen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,24]]},"reference":[{"issue":"3","key":"2055_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"2055_CR2","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1186\/s12889-024-19104-6","volume":"24","author":"JL Lin","year":"2024","unstructured":"Lin JL, Lin JX, Lin GT, et al. Global incidence and mortality trends of gastric cancer and predicted mortality of gastric cancer by 2035. BMC Public Health. 2024;24(1):1763.","journal-title":"BMC Public Health"},{"issue":"16","key":"2055_CR3","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.3748\/wjg.v29.i16.2452","volume":"29","author":"WJ Yang","year":"2023","unstructured":"Yang WJ, Zhao HP, Yu Y, et al. Updates on global epidemiology, risk and prognostic factors of gastric cancer. World J Gastroenterol. 2023;29(16):2452\u201368.","journal-title":"World J Gastroenterol"},{"issue":"21","key":"2055_CR4","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1056\/NEJM197111182852108","volume":"285","author":"J Folkman","year":"1971","unstructured":"Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285(21):1182\u20136.","journal-title":"N Engl J Med"},{"issue":"7","key":"2055_CR5","doi-asserted-by":"publisher","first-page":"3075","DOI":"10.3390\/cimb44070212","volume":"44","author":"\u0141 Kruszyna","year":"2022","unstructured":"Kruszyna \u0141, Murawa D, Jagodzi\u0144ski PP, et al. The expression and prognostic significance of VEGF and CXCR4 in gastric cancer: correlation with angiogenesis, lymphangiogenesis and progression. Curr Issues Mol Biol. 2022;44(7):3075\u201388.","journal-title":"Curr Issues Mol Biol"},{"key":"2055_CR6","doi-asserted-by":"publisher","first-page":"1550752","DOI":"10.3389\/fimmu.2025.1550752","volume":"16","author":"J Li","year":"2025","unstructured":"Li J, Li Z, Wang K. Targeting angiogenesis in gastrointestinal tumors: strategies from vascular disruption to vascular normalization and promotion strategies angiogenesis strategies in GI tumor therapy. Front Immunol. 2025;16:1550752.","journal-title":"Front Immunol"},{"issue":"3","key":"2055_CR7","doi-asserted-by":"publisher","first-page":"311","DOI":"10.47162\/RJME.64.3.03","volume":"64","author":"A Giubelan","year":"2023","unstructured":"Giubelan A, Stancu MI, Hon\u0163aru SO, et al. Tumor angiogenesis in gastric cancer. Rom J Morphol Embryol. 2023;64(3):311.","journal-title":"Rom J Morphol Embryol"},{"issue":"23","key":"2055_CR8","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa032691","volume":"350","author":"H Hurwitz","year":"2004","unstructured":"Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350(23):2335\u201342.","journal-title":"N Engl J Med"},{"issue":"11","key":"2055_CR9","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/S1470-2045(14)70420-6","volume":"15","author":"H Wilke","year":"2014","unstructured":"Wilke H, Muro K, Van Cutsem E, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014;15(11):1224\u201335.","journal-title":"Lancet Oncol"},{"issue":"13","key":"2055_CR10","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1200\/JCO.2015.63.5995","volume":"34","author":"J Li","year":"2016","unstructured":"Li J, Qin S, Xu J, et al. Randomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction. J Clin Oncol. 2016;34(13):1448\u201354.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2055_CR11","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s13104-018-3137-8","volume":"11","author":"B Mawalla","year":"2018","unstructured":"Mawalla B, Yuan X, Luo X, et al. Treatment outcome of anti-angiogenesis through VEGF-pathway in the management of gastric cancer: a systematic review of phase II and III clinical trials. BMC Res Notes. 2018;11(1):21.","journal-title":"BMC Res Notes"},{"key":"2055_CR12","doi-asserted-by":"publisher","first-page":"1021772","DOI":"10.3389\/fonc.2022.1021772","volume":"12","author":"N Saoudi Gonzalez","year":"2022","unstructured":"Saoudi Gonzalez N, Castet F, Elez E, et al. Current and emerging anti-angiogenic therapies in gastrointestinal and hepatobiliary cancers. Front Oncol. 2022;12:1021772.","journal-title":"Front Oncol"},{"key":"2055_CR13","doi-asserted-by":"publisher","first-page":"1460533","DOI":"10.3389\/fimmu.2024.1460533","volume":"15","author":"Y Kang","year":"2024","unstructured":"Kang Y, Kang Y, Zhang D, et al. Antiangiogenic therapy exerts antitumor effects by altering the tumor microenvironment: bibliometric analysis. Front Immunol. 2024;15:1460533.","journal-title":"Front Immunol"},{"key":"2055_CR14","doi-asserted-by":"publisher","first-page":"1591059","DOI":"10.3389\/fonc.2025.1591059","volume":"15","author":"KQ Hou","year":"2025","unstructured":"Hou KQ, Wu JM, Chen J. Global research landscape of antiangiogenic therapy for colorectal cancer: a bibliometric analysis of mechanistic insights and clinical advancements. Front Oncol. 2025;15:1591059.","journal-title":"Front Oncol"},{"issue":"1","key":"2055_CR15","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1080\/13880209.2023.2288697","volume":"62","author":"G Zhang","year":"2024","unstructured":"Zhang G, Qin Y, Liu S, et al. Bibliometric analysis of research trends and topic areas in traditional Chinese medicine therapy for lymphoma. Pharm Biol. 2024;62(1):13\u201321.","journal-title":"Pharm Biol"},{"issue":"27","key":"2055_CR16","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000034228","volume":"102","author":"W Zheng","year":"2023","unstructured":"Zheng W, Wu Y, Wang Y, et al. Bibliometric and visualized analysis of the top-100 highly cited articles on immunotherapy for endometrial cancer. Medicine. 2023;102(27):e34228.","journal-title":"Medicine"},{"issue":"2","key":"2055_CR17","doi-asserted-by":"publisher","first-page":"417","DOI":"10.3390\/biomedicines10020417","volume":"10","author":"M Jadhao","year":"2022","unstructured":"Jadhao M, Chen CL, Liu W, et al. Endoglin modulates TGF\u03b2R2 induced VEGF and proinflammatory cytokine axis mediated angiogenesis in prolonged DEHP-exposed breast cancer cells. Biomedicines. 2022;10(2):417.","journal-title":"Biomedicines"},{"issue":"6","key":"2055_CR18","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1023\/A:1008600603059","volume":"20","author":"W Wynendaele","year":"1998","unstructured":"Wynendaele W, van Oosterom AT, Pawinski A, et al. Angiogenesis: possibilities for therapeutic interventions. Pharm World Sci. 1998;20(6):225\u201335.","journal-title":"Pharm World Sci"},{"issue":"30","key":"2055_CR19","doi-asserted-by":"publisher","first-page":"3968","DOI":"10.1200\/JCO.2011.36.2236","volume":"29","author":"A Ohtsu","year":"2011","unstructured":"Ohtsu A, Shah MA, Van Cutsem E, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol. 2011;29(30):3968\u201376.","journal-title":"J Clin Oncol"},{"issue":"11","key":"2055_CR20","first-page":"911","volume":"46","author":"X Yan","year":"2024","unstructured":"Yan X, Guo Y, Sun DL, et al. Drug resistance mechanism of anti-angiogenesis therapy in tumor. Yi Chuan. 2024;46(11):911\u20139.","journal-title":"Yi Chuan"},{"issue":"15","key":"2055_CR21","doi-asserted-by":"publisher","first-page":"3372","DOI":"10.1158\/1078-0432.CCR-15-0600","volume":"21","author":"SJ Casak","year":"2015","unstructured":"Casak SJ, Fashoyin-Aje I, Lemery SJ, et al. FDA approval summary: ramucirumab for gastric cancer. Clin Cancer Res. 2015;21(15):3372\u20136.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2055_CR22","doi-asserted-by":"publisher","first-page":"2427896","DOI":"10.1080\/16078454.2024.2427896","volume":"29","author":"W Zhang","year":"2024","unstructured":"Zhang W, Zhang K, Feng Y, et al. Global research trends in traditional Chinese medicine therapy for acute leukemia: a comprehensive visualization and bibliometric analysis. Hematology. 2024;29(1):2427896.","journal-title":"Hematology"},{"issue":"8","key":"2055_CR23","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1093\/jnci\/djp058","volume":"101","author":"A Komuro","year":"2009","unstructured":"Komuro A, Yashiro M, Iwata C, et al. Diffuse-type gastric carcinoma: progression, angiogenesis, and transforming growth factor beta signaling. J Natl Cancer Inst. 2009;101(8):592\u2013604.","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"2055_CR24","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1158\/1535-7163.MCT-14-0255","volume":"13","author":"ST Kim","year":"2014","unstructured":"Kim ST, Jang HL, Lee SJ, et al. Pazopanib, a novel multitargeted kinase inhibitor, shows potent in vitro antitumor activity in gastric cancer cell lines with FGFR2 amplification. Mol Cancer Ther. 2014;13(11):2527\u201336.","journal-title":"Mol Cancer Ther"},{"issue":"9911","key":"2055_CR25","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(13)61719-5","volume":"383","author":"CS Fuchs","year":"2014","unstructured":"Fuchs CS, Tomasek J, Yong CJ, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014;383(9911):31\u20139.","journal-title":"Lancet"},{"issue":"3","key":"2055_CR26","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/S1470-2045(18)30791-5","volume":"20","author":"CS Fuchs","year":"2019","unstructured":"Fuchs CS, Shitara K, Di Bartolomeo M, et al. Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20(3):420\u201335.","journal-title":"Lancet Oncol"},{"issue":"26","key":"2055_CR27","doi-asserted-by":"publisher","first-page":"3219","DOI":"10.1200\/JCO.2013.48.8585","volume":"31","author":"J Li","year":"2013","unstructured":"Li J, Qin S, Xu J, et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. J Clin Oncol. 2013;31(26):3219\u201325.","journal-title":"J Clin Oncol"},{"key":"2055_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fsurg.2022.743274","volume":"9","author":"P Gan","year":"2022","unstructured":"Gan P, Fan W, Zhang H, et al. The top-cited articles with a focus on Barrett\u2019s esophagus: a bibliometric analysis. Front Surg. 2022;9:743274.","journal-title":"Front Surg"},{"issue":"23","key":"2055_CR29","doi-asserted-by":"publisher","first-page":"5875","DOI":"10.1158\/1078-0432.CCR-14-1071","volume":"20","author":"M Javle","year":"2014","unstructured":"Javle M, Smyth EC, Chau I. Ramucirumab: successfully targeting angiogenesis in gastric cancer. Clin Cancer Res. 2014;20(23):5875\u201381.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"2055_CR30","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1038\/bjc.2016.293","volume":"115","author":"CS Fuchs","year":"2016","unstructured":"Fuchs CS, Tabernero J, Tom\u00e1\u0161ek J, et al. Biomarker analyses in REGARD gastric\/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab. Br J Cancer. 2016;115(8):974\u201382.","journal-title":"Br J Cancer"},{"issue":"12","key":"2055_CR31","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1007\/s40273-017-0528-y","volume":"35","author":"NC B\u00fcy\u00fckkaramikli","year":"2017","unstructured":"B\u00fcy\u00fckkaramikli NC, Blommestein HM, Riemsma R, et al. Ramucirumab for treating advanced gastric cancer or gastro-oesophageal junction adenocarcinoma previously treated with chemotherapy: an evidence review group perspective of a NICE single technology appraisal. Pharmacoeconomics. 2017;35(12):1211\u201321.","journal-title":"Pharmacoeconomics"},{"key":"2055_CR32","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.ejca.2020.06.007","volume":"137","author":"YJ Bang","year":"2020","unstructured":"Bang YJ, Golan T, Dahan L, et al. Ramucirumab and durvalumab for previously treated, advanced non-small-cell lung cancer, gastric\/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia\/b study (JVDJ). Eur J Cancer. 2020;137:272\u201384.","journal-title":"Eur J Cancer"},{"issue":"3","key":"2055_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e24757","volume":"10","author":"L Zhang","year":"2024","unstructured":"Zhang L, Zhou X, Zhao J, et al. Research hotspots and frontiers of preconditioning in cerebral ischemia: a bibliometric analysis. Heliyon. 2024;10(3):e24757.","journal-title":"Heliyon"},{"issue":"4","key":"2055_CR34","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/nrd2115","volume":"6","author":"J Folkman","year":"2007","unstructured":"Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov. 2007;6(4):273\u201386.","journal-title":"Nat Rev Drug Discov"},{"issue":"9","key":"2055_CR35","doi-asserted-by":"publisher","first-page":"686","DOI":"10.4251\/wjgo.v11.i9.686","volume":"11","author":"HL Hsieh","year":"2019","unstructured":"Hsieh HL, Tsai MM. Tumor progression-dependent angiogenesis in gastric cancer and its potential application. World J Gastrointest Oncol. 2019;11(9):686\u2013704.","journal-title":"World J Gastrointest Oncol"},{"issue":"10294","key":"2055_CR36","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398(10294):27\u201340.","journal-title":"Lancet"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-025-02055-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-025-02055-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-025-02055-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T05:18:51Z","timestamp":1768972731000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11096-025-02055-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,24]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["2055"],"URL":"https:\/\/doi.org\/10.1007\/s11096-025-02055-2","relation":{},"ISSN":["2210-7711"],"issn-type":[{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,24]]},"assertion":[{"value":"7 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study did not include human participants, animals, or other identifiable personal data. As the analysis was based solely on publicly available bibliographic records from the WoSCC, ethical approval and informed consent were not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}